A Risk-Benefit Assessment of the Levonorgestrel-Releasing Intrauterine System
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
The levonorgestrel-releasing intrauterine system (LNG-IUS), has been developed by Leiras Pharmaceuticals, Turku, Finland. It is a new systemic hormonal contraceptive that releases levonorgestrel 20 micrograms every 24 hours. The device provides fertility control comparable with that of female sterilisation, complete reversibility and convenience, and has an excellent tolerability record. The low dosage of levonorgestrel released by its unique delivery system ensures minimal hormone-related systemic adverse effects, which tend to be in the category of 'nuisance' rather than hazardous, and gradually diminish after the first few months of use. In some respects, the contraceptive characteristics of the LNG-IUS have over-shadowed a substantial range of noncontraceptive beneficial effects that are rarely seen with inert or copper-releasing intrauterine contraceptive devices (IUDs), and have important and positive gynaecological and public health implications. This applies particularly to the profound reduction in duration and quantity of menstrual bleeding, and alleviation of dysmenorrhoea, which are associated with the use of the device. Recent studies have shown that the LNG-IUS is effective in preventing endometrial proliferation associated with oral or transdermal estradiol therapy, and in inducing regression of endometrial hyperplasia. Further research is required to determine whether it has a role in regulating the growth of uterine fibroids, and preventing pelvic inflammator…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with women without diabetes, women with diabetes using an intrauterine device (copper or levonorgestrel-releasing) are not at increased risk of untoward effects (226–230).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [229]
Citations
Cites
Hallberg, L., Hôgdahl, A., Nilsson, L., & Rybo, G. (1966) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016346609158455 · Cited by 966
Andersson, K., Odlind, V., & Rybo, G. (1994) · Contraception · doi:10.1016/0010-7824(94)90109-0 · Cited by 491
Levonorgestrel‐releasing intrauterine device in the treatment of menorrhagia
ANDERSSON, J. K., & RYBO, G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb16240.x · Cited by 356
Endometrial Morphology During Long-Term Use of Levonorgestrel-Releasing Intrauterine Devices
Silverberg, S. G., Haukkamaa, M., Arko, H., Nilsson, C. G., & Luukkainen, T. (1986) · International Journal of Gynecological Pathology · doi:10.1097/00004347-198609000-00005 · Cited by 262
Irving, S., Stern, J., & International committee for contraception research (ICCR) (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56455-3 · Cited by 247
Sivin, I., Stern, J., Coutinho, E., Mattos, C. E. R., El Mahgoub, S., Diaz, S., Pavez, M., Alvarez, F., Brache, V., Thevenin, F., et al. (1991) · Contraception · doi:10.1016/0010-7824(91)90149-a · Cited by 232
TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD
NILSSON, C. G., HAUKKAMAA, M., VIEROLA, H., LUUKKAINEN, T., & ARCANGELI, P. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb01625.x · Cited by 215
Levonorgestrel-Releasing Intrauterine Device
Luukkainen, T., Lähteenmäki, P., & Toivonen, J. (1990) · Annals of Medicine · doi:10.3109/07853899009147248 · Cited by 207
TOIVONEN, J., LUUKKAINEN, T., & ALLONEN, H. (1991) · Obstetrics & Gynecology · doi:10.1097/00006250-199102000-00019 · Cited by 195
Sivin, I., Mahgoub, S. E., McCarthy, T., Mishell, D. R., Shoupe, D., Alvarez, F., Brache, V., Jimenez, E., Diaz, J., Faundes, A., et al. (1990) · Contraception · doi:10.1016/0010-7824(90)90046-x · Cited by 179
Cited by
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
SOGC Clinical Practice Guidelines
Lalonde, A. B. (1995) · Journal SOGC · doi:10.1016/s1701-2163(16)30568-0 · Cited by 306
Stewart, A., Cummins, C., Gold, L., Jordan, R., & Phillips, W. (2001) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2001.00020.x · Cited by 156
Kingman, C. E. C., Kadir, R. A., Lee, C. A., & Economides, D. L. (2004) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2004.00305.x · Cited by 182
Cox, M. L., Tripp, J. H., & Blacksell, S. (2002) · Journal of Family Planning and Reproductive Health Care · doi:10.1783/147118902101196225 · Cited by 80
Metadata
- Authors
- Sturridge, F., & Guillebaud, J.
- ORCID
- Guillebaud, John
- Venue
- Drug Safety
- Published
- 1996-12
- Volume
- 15
- Issue
- 6
- Pages
- 430-440
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2144897291
- Cited by
- 69
- References
- 61
- Citations by year
- 2026: 1 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 1
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Social Sciences › Political Science and International Relations › International Human Rights and Reproductive Law
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- levonorgestrel-releasing intrauterine system, hormonal intrauterine device, contraceptive safety, non-contraceptive benefits, menstrual bleeding reduction, dysmenorrhea, endometrial hyperplasia, endometrial proliferation, uterine fibroids, pelvic inflammatory disease, ovarian cysts, ovarian function, patient counseling
- MeSH terms
- Delayed-Action Preparations, Female, Humans, Intrauterine Devices, Medicated, Levonorgestrel, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Risk-Benefit Assessment of the Levonorgestrel-Releasing Intrauterine System. https://app.cochat.ai/papers/10.2165/00002018-199615060-00006
- The paper
- Sturridge, F., & Guillebaud, J. (1996). A Risk-Benefit Assessment of the Levonorgestrel-Releasing Intrauterine System. Drug Safety. https://doi.org/10.2165/00002018-199615060-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.